利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

135 条记录 (耗时 0.045 秒)

    Imidazolidine-based metal carbene metathesis catalysts
    62.
    发明授权
    Imidazolidine-based metal carbene metathesis catalysts 有权
    咪唑烷系金属卡宾复分解催化剂

    公开(公告)号：US08846939B2

    公开(公告)日：2014-09-30

    申请号：US13494708

    申请日：2012-06-12

    申请人： Robert H. Grubbs ,  Matthias Scholl

    发明人： Robert H. Grubbs ,  Matthias Scholl

    IPC分类号： C07F15/00

    CPC分类号： C07F15/0046 ,  B01J31/2273 ,  B01J31/2278 ,  B01J31/2295 ,  B01J2231/543 ,  B01J2531/821 ,  B01J2531/825 ,  C08G61/08

    摘要： The present invention relates to novel metathesis catalysts with an imidazolidine-based ligand and to methods for making and using the same. The inventive catalysts are wherein: M is ruthenium or osmium; X and X1 are each independently an anionic ligand; L is a neutral electron donor ligand; and, R, R1 R6, R7, R8, and R9 are each independently hydrogen or a substituent selected for the group consisting of C1 C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, aryl, C1-C20 alkoxycarbonyl, C1-C20 alkyithiol, aryl thiol, C1-C20 alkylsulfortyl and C1-C20 alkylsulfinyl, the substituent optionally substituted with one or more moieties selected from the group consisting of C1-C20 alkyl, C1-C10 alkoxy, aryl, and a functional group. The inclusion of an imidazolidine ligand to the previously described ruthenium or osmium catalysts has been found to dramatically improve the properties of these complexes.

    摘要翻译： 本发明涉及具有咪唑烷类配体的新型复分解催化剂及其制备和使用方法。 本发明的催化剂是其中：M是钌或锇; X和X1各自独立地为阴离子配体; L是中性电子给体配体; 并且，R 1，R 1，R 6，R 7，R 8和R 9各自独立地为氢或选自由C 1 -C 20烷基，C 2 -C 20烯基，C 2 -C 20炔基，芳基，C 1 -C 20烷氧基羰基，C 1 -C 20 烷基硫醇，芳基硫醇，C 1 -C 20烷基磺酰基和C 1 -C 20烷基亚磺酰基，所述取代基任选被一个或多个选自C 1 -C 20烷基，C 1 -C 10烷氧基，芳基和官能团的部分取代。 已经发现将咪唑烷配体包含在前述的钌或锇催化剂中可显着地改善这些络合物的性质。

    PREPARATION OF SATURATED IMIDAZOLINIUM SALTS AND RELATED COMPOUNDS
    67.
    发明申请
    PREPARATION OF SATURATED IMIDAZOLINIUM SALTS AND RELATED COMPOUNDS 有权
    饱和脂肪酸钠盐及相关化合物的制备

    公开(公告)号：US20110087032A1

    公开(公告)日：2011-04-14

    申请号：US12741568

    申请日：2008-11-10

    申请人： Kevin Kuhn ,  Robert H. Grubbs

    发明人： Kevin Kuhn ,  Robert H. Grubbs

    IPC分类号： C07D233/06

    CPC分类号： C07D233/06 ,  C07D239/06

    摘要： Methods for the preparation of saturated imidazolinium salts and related compounds that comprises reaction of formamidines with compounds such as dihaloethane and an optional base are disclosed. Alternatively, the imidazolinium salts and related compounds can be prepared in a one-step process without purification of the formamidine reactant. These methods make it possible to obtain numerous imidazolinium salts and related compounds under solvent-free reaction conditions and in excellent yields.

    摘要翻译： 公开了制备饱和咪唑啉盐和相关化合物的方法，其包括甲酰胺与诸如二卤代乙烷和任选碱的化合物的反应。 或者，咪唑啉鎓盐和相关化合物可以以一步法制备而不净化甲脒反应物。 这些方法使得可以在无溶剂反应条件下以优异的产率获得许多咪唑啉鎓盐和相关化合物。

    TREATMENT FOR EYE DISORDER
    70.
    发明申请
    TREATMENT FOR EYE DISORDER 有权
    治疗眼病

    公开(公告)号：US20080286255A1

    公开(公告)日：2008-11-20

    申请号：US12126100

    申请日：2008-05-23

    申请人： DANIEL M. SCHWARTZ ,  Scott Fraser ,  Robert H. Grubbs ,  Justin P. Gallivan ,  Changjun Yu

    发明人： DANIEL M. SCHWARTZ ,  Scott Fraser ,  Robert H. Grubbs ,  Justin P. Gallivan ,  Changjun Yu

    IPC分类号： A61K38/43 ,  A61P27/02

    CPC分类号： A61K49/0056 ,  A61K38/482 ,  A61K41/00 ,  A61K49/0017

    摘要： The present invention relates to altering the physical and/or chemical properties of at least part of at least one tissue in the eye. In a specific embodiment, it relates to the treatment of any eye disorder, although in particular embodiments the individual has a thickened Bruch's membrane. An activating energy source is utilized to effect a controlled diffusion enhancement and/or degradation of Bruch's membrane that enables improved diffusional transport between the choroid and retina. The individual is administered an inactivated diffusion-enhancing molecule that becomes associated with the membrane, which is then precisely exposed to an activating energy source, such as light or ultrasound.

    摘要翻译： 本发明涉及改变眼睛中至少一个组织的至少一部分的物理和/或化学性质。 在具体实施方案中，它涉及任何眼睛疾病的治疗，尽管在具体实施方案中个体具有增厚的布鲁赫氏膜。 使用活化能源来实现Bruch膜的受控扩散增强和/或降解，其能够改善脉络膜和视网膜之间的扩散转运。 给个体施用与膜相关的失活的扩散增强分子，然后将其精确地暴露于诸如光或超声的活化能源。